Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xuhui Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Adv Exp Med Biol. 2023;1442:85-104. doi: 10.1007/978-981-99-7471-9_6.
Cord blood (CB) has been proven to be an alternative source of haematopoietic stem cells (HSCs) for clinical transplantation and has multiple advantages, including but not limited to greater HLA compatibility, lower incidence of graft-versus-host disease (GvHD), higher survival rates and lower relapse rates among patients with minimal residual disease. However, the limited number of HSCs in a single CB unit limits the wider use of CB in clinical treatment. Many efforts have been made to enhance the efficacy of CB HSC transplantation, particularly by ex vivo expansion or enhancing the homing efficiency of HSCs. In this chapter, we will document the major advances regarding human HSC ex vivo expansion and homing and will also discuss the possibility of clinical translation of such laboratory work.
脐带血 (CB) 已被证明是临床移植造血干细胞 (HSCs) 的另一种来源，具有多种优势，包括但不限于更高的 HLA 相容性、更低的移植物抗宿主病 (GvHD) 发生率、更高的生存率和更低的微小残留病患者的复发率。然而，单个 CB 单位中 HSCs 的数量有限，限制了 CB 在临床治疗中的更广泛应用。已经做出了许多努力来增强 CB HSC 移植的疗效，特别是通过体外扩增或增强 HSCs 的归巢效率。在本章中，我们将记录有关人 HSC 体外扩增和归巢的主要进展，并将讨论此类实验室工作临床转化的可能性。
